Lineage Cell Therapeutics
LCTX
LCTX
101 hedge funds and large institutions have $103M invested in Lineage Cell Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
9% less capital invested
Capital invested by funds: $112M → $103M (-$9.71M)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
Holders
101
Holding in Top 10
4
Calls
$268K
Puts
$17K
Top Buyers
| 1 | +$3.83M | |
| 2 | +$1.33M | |
| 3 | +$987K | |
| 4 |
E
Ergoteles
New York
|
+$875K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$600K |
Top Sellers
| 1 | -$9.56M | |
| 2 | -$2.63M | |
| 3 | -$1.62M | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.31M |
| 5 |
JPMorgan Chase & Co
New York
|
-$937K |